Mark Wegter, economist, joined LSP in 1998 and became a general partner in early 2001. He currently serves as Chairman of the supervisory board of Kiadis Pharma (NL/CDN) and as a supervisory board member for PamGene (NL), OncoMethylome Sciences (B), 4-Antibody (CH/G) and EyeSense (CH/G). He was also on the Supervisory Board of Jerini (G) until the company was listed on the Frankfurt stock exchange in November 2005. Mark has been involved in many of LSP’s investments, both early- and later-stage, including U-BiSys (NL) (which became Crucell after it merged with yet another of LSP’s portfolio companies), deVGen (B) (which was listed on the Euronext stock exchange in 2005), De Novo Pharmaceuticals (UK) and Kreatech Biotechnology (NL). He established LSP’s Munich office in late 2001 and has since extended LSP’s foothold in Germany and Switzerland, together with Joachim Rothe.
Mark started his career at ING Barings Investment Banking in Amsterdam and São Paulo, where he worked as a senior analyst on Global Risk Management and served as the assistant to a member of the executive committee, with worldwide responsibility for risk management. Mark has a Masters degree in business economics from the Erasmus University of Rotterdam.
